Full - transcriptome analysis of miRNA expression in mononuclear cells in patients with acute decompensation of chronic heart failure of various etiologies


Cite item

Full Text

Abstract

It is known that micro RNAs are an important regulatory element in the pathogenesis of many diseases, including cardiovascular diseases. Different levels of expression of these molecules in various pathologies makes miRNA a potential diagnostic and prognostic biomarker. Aim. Analysis of miRNA expression levels in mononuclear blood cells (MBC) of patients with acute decompensation f chronic heart failure (CHF) of various etiologies and evaluation of the possibility of their use as a biological marker. Materials and methods. 7 male patients with acute decompensation of CHF with a reduced ejection fraction (EF), NYHA functional class II-IV (FC) according to NYHA [mean (M) EF 29.2%, standard deviation (SD) 13.27%] in age 38 to 65 years old [median (Me) 58 years]. In 3 patients, heart failure developed as a result of dilated cardiomyopathy (DCMP), in 4 patients - against the background of post - infarction cardiosclerosis of the ischemic nature [group of patients with coronary heart disease (CHD)]. The control group - 5 age - matched (from 41 to 57 years old, Me 49 years old) healthy male volunteers. A complete transcript analysis of miRNA expression in MNCs was performed for all patients and healthy volunteers. Results. Differentially expressed miRNAs were determined in patients with CHF (regardless of etiology) compared with healthy individuals: miR-182, miR-144, miR-183, miR-486-5p, miR-143 (log2FC >1, FDR p - value <0.05). When comparing miRNA profiles in IHD or DCMP groups with miRNA profile in healthy individuals of the control group in IHD group, a significant increase in miR-182, miR-486-5p, miR-183, miR-144, miR-144*, miR-451 expression was detected , miR-143, miR-1180 and a decrease in the expression of miR-204, miR-99a (-1 1, FDR p - value <0.05), and in patients with DCMP there was a decrease in the expression of miR-143 and miR-10b (log2FC <-1, FDR p - value <0.05). Conclusion. Based on the results of full - transcriptome sequencing, miRNAs associated with the development of CHF with a reduced left ventricular EF on the background of the existing post - infarction cardiosclerosis were detected.

About the authors

I V Zhirov

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology; Russian Medical Academy of Continuing Professional Education

Email: izhirov@mail.ru
д.м.н., в.н.с. отд. заболеваний миокарда и сердечной недостаточности НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России; e-mail: izhirov@mail.ru; ORCID: 0000-0002-4066-2661 Moscow, Russia

N M Baulina

Institute of Experimental Cardiology, National Medical Research Center of Cardiology

н.с. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0001-8767-2958 Moscow, Russia

S N Nasonova

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology

к.м.н., с.н.с. отд. заболеваний миокарда и сердечной недостаточности НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0002-0920-7417 Moscow, Russia

G Zh Osmak

Institute of Experimental Cardiology, National Medical Research Center of Cardiology

м.н.с. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0001-7474-8095 Moscow, Russia

N A Matveyeva

Institute of Experimental Cardiology, National Medical Research Center of Cardiology

к.б.н., с.н.с. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0002-4369-2882 Moscow, Russia

D R Mindzaev

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology

аспирант отд. заболеваний миокарда и сердечной недостаточности НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0002-2236-3959 Moscow, Russia

O O Favorova

Institute of Experimental Cardiology, National Medical Research Center of Cardiology

д.б.н., проф., г.н.с. лаб. функциональной геномики сердечно-сосудистых заболеваний Института экспериментальной кардиологии ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0002-5271-6698 Moscow, Russia

S N Tereshchenko

Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology; Russian Medical Academy of Continuing Professional Education

д. м. н., проф., первый зам. ген. дир-ра, зам. ген. дир-ра по научной работе, рук. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии» Минздрава России; ORCID: 0000-0001-9234-6129 Moscow, Russia

References

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.
  2. Ziaeian B, Fonarow G.C. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78.
  3. Fuat A, Murphy J.J, Hungin A.P.S, Curry J, Mehrzad A.A, Hetherington A, Johnston J.I, Smellie W.S.A, Duffy V, Cawley P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56:327-33.
  4. Kelder J.C, Cowie M.R, Mc Donagh T.A, Hardman S.M, Grobbee D.E, Cost B, Hoes A.W. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta - analysis. Heart. 2011;97:959-63.
  5. Weber J.A, Baxter D.H, Zhang S, Huang D.Y, Huang K.H, Lee M.J, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733-41.
  6. Kumar S, Williams D, Sur S, Wang J.Y, Jo H. Role of flow - sensitive microRNAs and long noncoding RNAs and in vascular dysfunction and atherosclerosis. Vascular pharmacology. 2018 Oct 7; pii: S1537-1891(18)30123-X. doi: 10.1016/j.vph.2018.10.001. Epub ahead of print
  7. Жиров И.В., Кочетов А.Г., Засеева А.В., Лянг О.В., Скворцов А.А., Абрамов А.А., Гимадиев Р.Р., Масенко В.П., Трещенко С.Н. МикроРНК в диагностике хронической сердечной недостаточности: состояние проблемы и результаты пилотного исследования. Системные Гипертензии. 2016;13(1):39-46.
  8. Ikitimur B, Cakmak H.A, Coskunpinar E, Barman H.A, Vural V.A. The relationship between circulating microRNAs and left ventricular mass in symptomatic heart failure patients with systolic dysfunction. Kardiol Pol. 2015;73(9):740-6.
  9. Cakmak H.A, Coskunpinar E, Ikitimur B, Barman H.A, Karadag B, Tiryakioglu N.O, Kahraman K, Vural V.A. The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome - wide expression study. J Cardiovasc Med (Hagerstown). 2015 Jun;16(6):431-7.
  10. Mukai N, Nakayama Y, Murakami S, Tanahashi T, Sessler D.I, Ishii S, Ogawa S, Tokuhira N, Mizobe T, Sawa T, Nakajima Y. Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease. Pediatr Res. 2018 Apr;83(4):866-73.
  11. Huang F, Huang X.Y, Yan D.S, Zhou X, Yang D.Y. MicroRNA-144 over - expression induced myocytes apoptosis. Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Apr;39(4):353-7.
  12. Li J, Cai S.X, He Q, Zhang H, Friedberg D, Wang F, Redington A.N. Intravenous miR-144 reduces left ventricular remodeling after myocardial infarction. Basic Res Cardiol. 2018 Aug 6;113(5):36.
  13. Chen B, Luo L, Wei X, Gong D, Jin L. Altered Plasma miR-144 as a Novel Biomarker for Coronary Artery Disease. Ann Clin Lab Sci. 2018 Jul;48(4):440-5.
  14. Ren J, Zhang J, Xu N, Han G, Geng Q, Song J, Li S, Zhao J, Chen H. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013 Dec 5;8(12):e80738.
  15. Zhang J, Ren J.Y, Chen H, Han G.P. Statins decreases expression of five inflammation - associated microRNAs in the plasma of patients with unstable angina. Beijing Da Xue Xue Bao Yi Xue Ban. 2015 Oct 18;47(5):761-8.
  16. Wang S, Yang M.H, Wang X.Y, Lin J, Ding Y.Q. Increased expression of miRNA-182 in colorectal carcinoma: an independent and tissue - specificprognostic factor. Int J Clin Exp Pathol. 2014 May 15;7(6):3498-503.
  17. Zhang Y, Guan D.H, Bi R.X, Xie J, Yang C.H, Jiang Y.H. Prognostic value of microRNAs in gastric cancer: a meta - analysis. Oncotarget. 2017 Jun 21;8(33):55489-510.
  18. Ромакина В.В., Жиров И.В., Насонова С.Н., Засеева А.В., Кочетов А.Г., Лянг О.В., Терещенко С.Н. МикроРНК как биомаркеры сердечно - сосудистых заболеваний: большие возможности малых молекул. Кардиология. 2018;58(1):66-71. doi: 10.18087/cardio.2018.1.10083
  19. Baulina N, Osmak G, Kiselev I, Matveeva N, Kukava N, Shakhnovich R, Kulakova O, Favorova O. NGS-identified circulating miR-375 as a potential regulating component of myocardial infarction associated network. J Mol Cell Cardiol. 2018 Aug;121:173-9. doi: 10.1016/j.yjmcc.2018.07.129

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies